Nolan Townsend, Lexeo Therapeutics CEO
October 30, 2023 08:54 AM EDTUpdated 10:49 AM
Financing
Startups
Cell/Gene Tx

Lex­eo Ther­a­peu­tics pen­cils in $113M IPO for car­diac and Alzheimer's gene ther­a­py read­outs in 2024

Kyle LaHucik

Senior Reporter

Ex­ec­u­tives at gene ther­a­py start­up Lex­eo Ther­a­peu­tics will like­ly make the 25-minute trek from their head­quar­ters to Nas­daq’s trad­ing floor lat­er this week in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Evotec gains on Halozyme's takeover pro­pos­al

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Adap­ti­m­mune to 're­de­fine' it­self as a sar­co­ma biotech, cuts a third of staffers

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

ALX On­col­o­gy hires Genen­tech, Mi­rati vet as CMO; Af­ter Car­mot, Heather Turn­er has three new roles on tap

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times